KYMOS

Percutaneous Absorption

In vitro Release Test and Trasdermal Permeation of topical formulations by Franz diffusion cells

KYMOS PHARMA SERVICES, S.L.

www.kymos.com

Kymos Pharma Services S.L.
Parc Tecnològic del Vallès
Ronda Can Fatjò, 7B
08290 Cerdanyola del Vallès
Barcelona, Spain

Phone (+34) 93 548 18 48
Fax: (+34) 93 170 29 99
info@kymos.es

PH PHARMAPROGRESS
a KYMOS company

www.pharmaprogress.com

Pharmaprogress S.r.l.
Via Alessandro Volta 12
60020 Camerata Picena
Ancona, Italy

Phone (+39) (0) 71 749 99 19
Fax (+39) (0) 71 749 63 41
info@pharmaprogress.com

IN VITRO RELEASE TEST

— Optimization and comparison of different formulations during formulation development phase.

— Development and validation of release rate methods for topical formulations.

— Quality control for *in vitro* release of manufacturing batches

In vitro method development in compliance with SUPAC-SS and FDA requirements. *(Guidance for Industry: SUPAC_SS: Nonsterile Semisolid Dosage Forms. FDA, 1997)*

IN VITRO PERMEATION TEST

— Determination of percutaneous absorption including flux rates and transdermal permeability of the active compounds.

— Penetration studies :
· Quantification of the API remaining in the skin
· Penetration in mucous membranes
· Penetration in cornea

— Applications:
· Optimization and comparison of formulations
· Selection of suitable excipients
· Selection of lead candidate formulations for topical products
· Assessment of safety of cosmetic actives

Permeation studies are performed in accordance with OECD and EMA guidelines *(Guideline for the testing of chemicals. Skin absorption: in vitro method. OECD 428, 2004; Guidance document for the conduct of skin absorption studies. OECD 28, 2004; EMA Guideline on quality of transdermal patches. EMA, 2014)*